Buy EG-018 online

EG-018 is a synthetic cannabinoid compound with the CAS number 2219320-91-7, featuring a carbazole-based structure that acts as a partial agonist of CB1 and CB2 receptors. This research chemical is available for purchase at Davechemicals.com, where we provide high-purity analytical reference standards for forensic and scientific applications. EG-018 represents an analogue of JWH-018 with a benzene ring modification, offering researchers a unique compound for studying cannabinoid receptor interactions.

What is EG-018 (CAS Number 2219320-91-7)

In the ever-evolving landscape of synthetic cannabinoids, EG-018 has emerged as a compound of significant interest within the research community. As a member of the aminoalkylindole class of synthetic cannabinoids, EG-018 (CAS Number 2219320-91-7) has garnered attention for its unique chemical structure and receptor binding properties. At Davechemicals.com, we understand the importance of providing researchers with access to high-quality reference materials, and EG-018 stands as one such compound that continues to be studied for its pharmacological profile and potential applications in scientific research.

The synthetic cannabinoid market has seen rapid development over the past decade, with compounds like EG-018 representing the sophisticated chemical modifications that clandestine laboratories employ to create novel substances. Understanding the characteristics of these compounds is crucial for researchers, law enforcement, and public health officials alike. Our commitment at Davechemicals.com is to provide accurate information and high-purity materials for legitimate research purposes.

Chemical Structure and Properties

EG-018 features a distinctive chemical structure that differentiates it from other synthetic cannabinoids. The compound’s systematic name is 1-naphthalenyl(9-pentyl-9H-carbazol-3-yl)methanone, reflecting its complex molecular architecture.

Table 1: EG-018 Chemical Properties

Property	Value
CAS Number	2219320-91-7
Molecular Formula	C₂₈H₂₅NO
Molecular Weight	391.51 g/mol
Purity	≥98% (analytical reference standard)
Physical Form	Crystalline solid
Solubility	0.2 mg/mL in DMSO, 20 mg/mL in DMF
Storage	-20°C recommended

The chemical structure of EG-018 consists of a naphthoyl group attached to a carbazole-based aminoalkylindole moiety, with a benzene ring modification that distinguishes it from its parent compound JWH-018. This structural variation significantly impacts its receptor binding affinity and efficacy profile.

Pharmacology and Receptor Interactions

Research into EG-018’s pharmacological properties reveals interesting characteristics that set it apart from other synthetic cannabinoids. Studies have shown that EG-018 exhibits high affinity for both CB1 and CB2 receptors, with binding affinities of 21 nM and 7 nM, respectively.

However, unlike many synthetic cannabinoids that act as full agonists, EG-018 behaves as a weak partial agonist in GTPγS binding assays. This means it produces receptor activation with lower efficacy compared to compounds like THC, despite having greater potency at CB1 receptors. The compound’s signalling profile suggests it may produce cannabinoid effects through different mechanisms than traditional full agonists.

Table 2: EG-018 Receptor Binding Data

Receptor	Binding Affinity (nM)	Efficacy Profile
CB1	21	Weak partial agonist
CB2	7	Weak partial agonist
Comparison to THC	–	Lower efficacy but greater potency at CB1

In vivo studies in mice have shown that EG-018 produces hypomotility, catalepsy, and hypothermia following intravenous administration, though these effects appear to be less pronounced than those produced by more potent synthetic cannabinoids. The compound’s ability to cross the blood-brain barrier and interact with cannabinoid receptors makes it a valuable tool for researchers studying the endocannabinoid system.

Legal Status Across Different Jurisdictions

The legal status of EG-018 varies significantly across different countries and regions, reflecting the complex regulatory landscape surrounding synthetic cannabinoids.

In Canada, EG-018 is classified as a Schedule II controlled substance, indicating its recognised potential for abuse and dependence. In Germany, the compound falls under the NpSG (New Psychoactive Substances Act), which restricts its use to industrial and scientific applications only. These regulatory classifications reflect the ongoing efforts by governments worldwide to control the distribution and use of novel psychoactive substances.

The legal status of synthetic cannabinoids remains fluid, with many countries implementing temporary bans or scheduling decisions as new compounds emerge. Researchers interested in studying EG-018 should verify current regulations in their specific jurisdiction before obtaining or using the compound.

Safety Considerations and Risks

Synthetic cannabinoids, including EG-018, carry potential risks that researchers and users should be aware of. The ADF (Australian Drug Foundation) has documented several serious side effects associated with synthetic cannabinoid use, including:

• Agitation, anxiety, and paranoia
• Aggressive and violent behavior
• Psychosis
• Irregular heartbeat and hypertension
• Breathing difficulties
• Seizures and stroke
• Acute kidney injury
• Severe hyperthermia

While these effects are more commonly associated with high-potency synthetic cannabinoids, the potential for adverse reactions exists with any compound that interacts with the endocannabinoid system. Researchers should exercise caution when handling EG-018 and follow appropriate safety protocols.

Frequently Asked Questions

What is EG-018 used for?

EG-018 is primarily used for scientific research purposes, particularly in studies investigating cannabinoid receptor interactions and the pharmacology of synthetic cannabinoids. It serves as a valuable tool for researchers studying the endocannabinoid system and developing new therapeutic approaches.

How does EG-018 compare to other synthetic cannabinoids?

EG-018 differs from many synthetic cannabinoids in its partial agonist profile. While most synthetic cannabinoids act as full agonists at CB1 receptors, EG-018 exhibits lower efficacy, producing milder effects. This makes it particularly interesting for researchers studying receptor signalling and partial agonism.

Is EG-018 legal?

The legal status of EG-018 varies by country. In Canada, it’s a Schedule II controlled substance, while in Germany, it’s regulated under the NpSG. Researchers should verify current regulations in their jurisdiction before obtaining or using EG-018.

What are the effects of EG-018?

Research suggests EG-018 produces cannabinoid-like effects, including relaxation and altered perception. However, as a partial agonist, its effects are generally milder than those of full agonist synthetic cannabinoids.

Where can I buy EG-018?

EG-018 is available for purchase at Davechemicals.com, where we provide high-purity analytical reference standards for legitimate research purposes. We ensure all customers are aware of the compound’s intended use and legal restrictions.

Conclusion and Next Steps

EG-018 represents an important compound in the study of synthetic cannabinoids and the endocannabinoid system. Its unique partial agonist properties make it a valuable tool for researchers seeking to understand cannabinoid receptor signaling and develop new therapeutic approaches.

At Davechemicals.com, we are committed to providing researchers with access to high-quality materials for legitimate scientific purposes. Our extensive catalog includes a wide range of research chemicals, including popular compounds like Buy Mescaline powder online | best Mescaline for sale online, Buy Bromonordiazepam Online, and many others.

For researchers interested in exploring the fascinating world of synthetic cannabinoids, EG-018 offers a unique opportunity to study receptor interactions and pharmacological profiles. We encourage you to explore our catalog and contact our team for more information about our products and research applications.

---

References

1. Gamage et al. (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacol Biochem Behav.
2. Castaneto et al. (2014). Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications. Mol Neurobiol.
3. Cohen & Weinstein (2018). The Effects of Cannabinoids on Executive Functions. Int J Environ Res Public Health.
4. Cayman Chemical. EG-018 Product Information.
5. Wikipedia. EG-018.
6. UNODC. Synthetic cannabinoids in herbal products.